US · ALDX
Aldeyra Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Lexington, MA 02421
- Website
- aldeyra.com
Price · as of 2025-12-31
$1.59
Market cap 328.49M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $10.41 | ||||
| 2015 | $4.29 | ||||
| 2016 | $5.25 | ||||
| 2017 | $8.80 | ||||
| 2018 | $7.53 | ||||
| 2019 | $3.52 | ||||
| 2020 | $12.52 | ||||
| 2021 | $4.10 | ||||
| 2022 | $7.18 | ||||
| 2023 | $3.62 | ||||
| 2024 | $6.35 | ||||
| 2025 | $5.62 |
AI valuation
Our deep-learning model estimates Aldeyra Therapeutics, Inc.'s (ALDX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.59
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALDX | Aldeyra Therapeutics, Inc… | $1.59 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| ACIU | AC Immune S.A. | $2.93 | 294.76M | +1,817% | -50% | — | — | -3.77 | 1.71 | 7.03 | -0.66 | — | 3.10 | -129.12% | -191.80% | -186.44% | -37.31% | -787.64% | -24.61% | 0.05 | -393.82 | 1.71 | 1.65 | 0.63 | -2031.00% | 8451.00% | -20663.00% | 34.00% | 0.65 | 981.44% | 0.00% | 0.00% | 0.00% | -0.61 | 0.49 | 1.17 | -1.52 |
| AMRN | Amarin Corporation plc | $13.80 | 285.42M | +2,553% | -43% | -73% | +374% | -2.65 | 0.45 | 0.95 | 0.93 | -7.95 | 0.46 | 35.60% | -40.15% | -35.95% | -15.83% | -41.74% | -10.83% | 0.02 | -13113.86 | 3.31 | 2.31 | 1.53 | 3333.00% | -2551.00% | -55089.00% | -14.25% | -0.17 | -14.11% | 0.00% | 0.00% | 0.00% | 0.75 | 2.21 | -0.30 | -2.13 |
| ANRO | Alto Neuroscience, Inc. | $19.69 | 611.7M | — | — | — | — | -1.42 | 0.58 | — | 0.93 | -1.67 | 0.58 | 0.00% | — | — | -153.99% | 95.25% | -46.51% | 0.11 | 49.90 | 16.92 | 16.81 | 2.20 | 8519.00% | — | 4594.00% | -56.68% | -4.74 | 68.72% | 0.00% | 0.00% | 90.14% | 0.93 | 1.29 | — | 0.72 |
| CADL | Candel Therapeutics, Inc. | $5.25 | 288.22M | — | — | — | — | -4.74 | 3.94 | — | -3.31 | -14.45 | 3.94 | 0.00% | — | — | -139.56% | 293.22% | -74.53% | 0.20 | -15.97 | 2.77 | 2.74 | 1.71 | 3282.00% | — | -2208.00% | -10.33% | -0.72 | 237.58% | 0.00% | 0.00% | 29.25% | -5.17 | -6.38 | — | 1.07 |
| CLLS | Cellectis S.A. | $3.88 | 389.18M | +21,055% | +605% | — | — | -3.10 | 0.87 | 2.74 | 5.83 | — | 0.87 | 77.88% | -143.48% | -88.57% | -34.02% | 165.71% | -10.22% | 0.70 | -7.99 | 1.73 | 1.70 | 5.47 | -7684.00% | 539748.00% | -17562.00% | 17.18% | 0.13 | -54.33% | 0.00% | 0.00% | 0.12% | 0.93 | -2.83 | -1.33 | -0.96 |
| CTNM | Contineum Therapeutics, I… | $15.34 | 560.36M | +1,304% | — | — | — | -3.10 | 0.66 | — | 1.61 | — | 0.66 | 0.00% | — | — | -64.95% | 27584.82% | -24.62% | 0.03 | — | 20.69 | 20.53 | 0.37 | -34222.00% | -10000.00% | -27618.00% | -25.46% | -3.29 | 18080.76% | 0.00% | 0.00% | 147.57% | 1.33 | 2.02 | — | 4.86 |
| GNLX | Genelux Corporation | $2.98 | 112.1M | +972% | — | — | +2,543% | -4.42 | 5.03 | 16511.63 | -3.56 | — | 5.03 | -11187.50% | -396200.00% | -373362.50% | -130.58% | 1604.05% | -95.41% | 0.07 | — | 4.57 | 4.48 | 0.23 | -1810.00% | -9529.00% | 145.00% | -16.36% | -3.08 | 1093.57% | 0.00% | 0.00% | 0.00% | -3.25 | -4.77 | 12883.26 | -2.91 |
| KYTX | Kyverna Therapeutics, Inc… | $8.21 | 359.53M | — | — | — | — | -0.78 | 0.37 | — | 1.42 | 0.00 | 0.37 | 0.00% | — | — | -80.74% | 2732.66% | -67.12% | 0.03 | -1004.25 | 8.61 | 8.47 | 0.71 | 332990000.00% | — | 11960.00% | -116.84% | -3.38 | 2231.58% | 0.00% | 0.00% | 63.02% | 1.25 | 1.53 | — | -0.17 |
| MREO | Mereo BioPharma Group plc | $0.37 | 59.17M | +8,875% | — | — | — | -8.52 | 6.04 | — | -7.48 | — | 6.11 | 0.00% | — | — | -77.58% | 2839.57% | -60.54% | 0.11 | -34.56 | 5.40 | 5.28 | 1.55 | -9997.00% | -10000.00% | 5560.00% | -9.10% | -2.37 | 2010.37% | 0.00% | 0.00% | 3.23% | -6.44 | -9.09 | — | 4.76 |
| SLN | Silence Therapeutics plc | $5.44 | 256.95M | +597% | -16% | — | — | -2.07 | 0.56 | 1.73 | 1.48 | — | 0.60 | 72.70% | -146.38% | -104.74% | -46.39% | 212.32% | -22.47% | 0.00 | — | 11.14 | 10.36 | 2.47 | -3190.00% | 7047.00% | 7223.00% | -90.74% | -4.02 | 227.52% | 0.00% | 0.00% | 70.57% | 1.14 | 1.07 | -1.67 | -2.43 |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- CEO
- Todd C. Brady
- Employees
- 9
- Beta
- 0.96
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.59) − 1 = — (DCF, example).